Voyager Therapeutics (NASDAQ:VYGR) Earns Overweight Rating from Cantor Fitzgerald

Voyager Therapeutics (NASDAQ:VYGR)‘s stock had its “overweight” rating restated by Cantor Fitzgerald in a research report issued on Wednesday,Benzinga reports.

VYGR has been the topic of a number of other research reports. Wedbush reaffirmed an “outperform” rating and set a $9.00 target price (down previously from $11.00) on shares of Voyager Therapeutics in a research note on Tuesday, February 11th. HC Wainwright reissued a “buy” rating and issued a $30.00 target price on shares of Voyager Therapeutics in a report on Monday, March 3rd. Citigroup began coverage on Voyager Therapeutics in a report on Monday, December 2nd. They issued a “buy” rating and a $12.00 target price on the stock. StockNews.com lowered Voyager Therapeutics from a “buy” rating to a “hold” rating in a research report on Friday, December 13th. Finally, Canaccord Genuity Group reiterated a “buy” rating and set a $14.00 price objective on shares of Voyager Therapeutics in a research report on Thursday, November 14th. One research analyst has rated the stock with a hold rating, eight have assigned a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat.com, the company has a consensus rating of “Buy” and an average price target of $15.72.

Voyager Therapeutics Price Performance

VYGR traded down $0.21 on Wednesday, hitting $3.76. The company had a trading volume of 180,059 shares, compared to its average volume of 356,028. The stock has a fifty day simple moving average of $4.95 and a 200-day simple moving average of $5.87. The firm has a market capitalization of $205.34 million, a P/E ratio of 5.28 and a beta of 0.99. Voyager Therapeutics has a 52-week low of $3.59 and a 52-week high of $10.66.

Voyager Therapeutics (NASDAQ:VYGR) last released its quarterly earnings results on Tuesday, March 11th. The company reported ($0.59) earnings per share for the quarter, missing the consensus estimate of ($0.35) by ($0.24). The firm had revenue of $4.39 million for the quarter, compared to the consensus estimate of $16.58 million. Voyager Therapeutics had a net margin of 15.80% and a return on equity of 8.33%. During the same quarter in the prior year, the firm earned $1.25 earnings per share. Equities research analysts expect that Voyager Therapeutics will post -0.91 earnings per share for the current fiscal year.

Insider Transactions at Voyager Therapeutics

In other Voyager Therapeutics news, COO Robin Swartz sold 6,500 shares of the firm’s stock in a transaction on Monday, December 23rd. The shares were sold at an average price of $5.65, for a total value of $36,725.00. Following the completion of the transaction, the chief operating officer now owns 112,328 shares of the company’s stock, valued at approximately $634,653.20. This trade represents a 5.47 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Insiders have sold a total of 10,778 shares of company stock valued at $58,548 in the last 90 days. Insiders own 4.53% of the company’s stock.

Institutional Investors Weigh In On Voyager Therapeutics

Hedge funds have recently added to or reduced their stakes in the business. Vestal Point Capital LP increased its position in shares of Voyager Therapeutics by 151.0% in the fourth quarter. Vestal Point Capital LP now owns 1,230,000 shares of the company’s stock valued at $6,974,000 after buying an additional 740,000 shares in the last quarter. Virtus Investment Advisers Inc. lifted its holdings in Voyager Therapeutics by 59.0% in the fourth quarter. Virtus Investment Advisers Inc. now owns 20,105 shares of the company’s stock valued at $114,000 after acquiring an additional 7,457 shares during the last quarter. Tema Etfs LLC purchased a new position in Voyager Therapeutics in the fourth quarter worth approximately $85,000. Man Group plc acquired a new stake in Voyager Therapeutics during the fourth quarter worth $234,000. Finally, Farallon Capital Management LLC raised its position in Voyager Therapeutics by 12.2% in the fourth quarter. Farallon Capital Management LLC now owns 2,570,700 shares of the company’s stock valued at $14,576,000 after purchasing an additional 278,700 shares during the period. 48.03% of the stock is owned by hedge funds and other institutional investors.

Voyager Therapeutics Company Profile

Voyager Therapeutics, Inc, a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial.